In December 2010, the National Institutes of Health, which owns the intellectual property rights for a manufacturing process for darunavir, put his patent for the drug to the patent pool. Johnson & Johnson holds patents remains the drug, and is actually blocking the manufacturers and others to darunavir at affordable prices for patients in developing countries. Continue reading
-
Recent Posts
- Topcon Launches First High-Definition multifocal lens for correcting presbyopia and astigmatism simultaneously
- Australian Nobel Prize Closer To provide vaccines in food after the first positive study in humans
- Common health problems of women of the basin
- Study shows link between weight Pitt Teen Girls’ and sexual behavior
- The diabetes drug Actos slows down arterial plaque
Archives
Categories
Blogroll